Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7680)	11/7/1998 1:57:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, in my opinion most people are engrossed in the sepsis part of Neuprex possible abilities. It is very hard for most to understand sepsis mode of action anyway, BUT do you think an article like the orange county register given national attention would make a difference in Xoma's stock price? If an article like this got national exposure, in my opinion we would have run up like ENMD, GERN, etc. Most people would better understand antibacterial versus antisepsis in my opinion. How much closer to possible approval is Xoma compared to a ENMD or GERN? Do you consider 20 billion dollar a year antibiotic market to be significant? Everyone should still consider though that Neuprex might not get approval. All above are just my opinions, like Bob always says in his posts also. I would like to thank everyone here on SI for their informative posts.